sic ickle cell dis isease in in Kaduna: the journey so far jo - - PowerPoint PPT Presentation

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie gr grant agr agreement No.

• . 82

8240 4021 21

Newborn screening (nbs) for sic ickle cell dis isease in in Kaduna: the jo journey so far

Livingstone G. Dogara

Department of Haematology, Faculty of Basic Clinical Sciences, Kaduna State University College of Medicine Kaduna NBS Working Group Sickle Cell Cohort Research Foundation (SCORE, www.scorecharity.com) Abuja

Affi filiations/Conflict of f In Interest

• Affiliations
• Kaduna State University
• Barau Dikko Teaching Hospital
• Africa Research and Innovative Initiative for Sickle Cell Education (ARISE)
• Sickle Cell Cohort Research Foundation (SCORE, www.scorecharity.com)

Abuja

• The Sickle Pan-African Research Consortium (SPARCO)
• Haemophilia Foundation of Nigeria
• Conflict of interest
• None

BDTH-KASU Haematology

• Inpatient services for paediatrics

sickle persons

• Inpatient services for adult sickle

persons

In Introduction

• What is the aim of the session?
• Effective communication and collaboration
• What will be covered in the session?
• Journey so far
• Little but giant steps

Screening

• Screening is defined as:

“a public health service in which members of a defined population, who do not necessarily perceive they are at risk of, or are already affected by, a disease or it’s complications, are asked a question or offered a test to identify those individuals who are more likely to be helped than harmed by further tests or treatment to reduce the risk of disease or it’s complication”

Second Report of the UK National Screening Committee

Newborn Screening

Why screen newborns for sickle cell disease?

• Early administration of prophylactic penicillin markedly reduces the incidence of

pneumococcal sepsis

• Clinical monitoring reduces morbidity and mortality
• Neonatal screening for β-thalassaemia major and other thalassaemias useful but

less important

Newborn Screening: Outcome

Overall outcome to be achieved

• Mortality rate in children of under 5 of less than 2 deaths per 100

affected infants Others

• Cascade family screening
• To target at risk families and offer future genetic choice
• To allow better Health Service resource planning

Nigeria Demography

Population Est. 200.96m (2019 proj.) Population Growth Rate: 2.6% (2017 est.) Birth Rate: 38.89 births/1000 births SCD births: >150,000/year in Nigeria Death Rate: 12.4 deaths/1,000 population (2017 est.)

Inusa, et al., Pediat Therapeut 2015, 5:3 DOI: 10.4172/2161-0665.1000262 https://nigerianstat.gov.ng › download

Population Est. 8.9m (2019 proj.) Population Growth Rate: 2.6% (2017 est.) Birth Rate: 38.89 births/1000 births Delivery by health professionals: 40.4% Delivery without assistance: 28.8% Facility based delivery rate: 32.4% Antenatal visit attendance: 30% (2008), 43.8% (2017) Kaduna Pilot NBS (2010-2011): 4000 babies

Inusa, et al., Pediat Therapeut 2015, 5:3 DOI: 10.4172/2161-0665.1000262 https://kdbs.ng/app/uploads/2019/06/KADUNA-STATE-SDGs-WATCH-1.pdf https://nigerianstat.gov.ng › download

Kaduna Sic ickle Cell Screening Programme – The id ideal

1) Antenatal Screening Programme

AIM: Identify mothers at risk of having an affected fetus

• High Prevalence (fetal prevalence SCD ≥1.5 / 10,000 pregnancies)
• Low Prevalence (fetal prevalence SCD <1.5 / 10,000 pregnancies)

2) Newborn screening Programme

• Universal

AIM: identify babies affected by SCD

3) Prenatal Diagnosis and DNA diagnostic services

AIM: To give a definitive diagnosis ARISE

Li Little but t Giant Steps

• 2009-2011: Pilot Study, Katsina/Kafanchan/London Sickle Cell Nigeria

Focus Group (Inusa, et al., Pediat Therapeut 2015, 5:3 DOI: 10.4172/2161-0665.1000262)

• 2013: NBS reagents exhausted
• 2014: Line of communications opened with KDSG
• 2016: ASH, AfroSicklenet, ASCAT (J Trop Dis Public Health. 2018; 6(2): 26)
• 2017-2018: Collaboration with partners
• 2019: RCPath LabSkill Africa/IEF CESTRA Installation training
• 2020: ASH CONSA

What do you want to know?

Source: Bennett and Rockwell, 1995, Targeting Outcomes of Programs

Social-economic-environmental impacts

2009-2017 Plan lannin ing Meetin ings – Katsin ina/Kafanchan/London SC SCD Nig igeria ia Focus Group

FGD 2017

ARISE/EHA: 2018-2019

Call ll to Actio ion: ASH Assessment vis isit it/LabSkill ll Afric ica 2018-2019

Ongoing

▪

Regular training workshops

▪

Policy review and updating

▪

Incident reporting and review

▪

Collection and review of key performance indicators

▪

Linking newborn and antenatal screening results

▪

Newborn outcomes project

Successes

• Government support and program approval
• MoU between SCORE and KDSG
• Academic and other partner support (BDTH, KASU, ABU, ABUTH, MOH, SPHCDA, Fantsuam

Foundation, SSCF)

• ASH CONSA support
• ARISE Exchange/RCPAth LabSkill Africa Standardization of diagnosis

and care

• Use of tools in management

Futuristic

• Ability to design a framework of inter-agency and intra-agency

collaboration

• Being ready for partnership and collaboration (ASH education

programme, BSH, Academic institution)

• Influencing national decision on guidelines for care of the sickle
• Develop framework/curriculum for holistic sickle care (Genetic counselling,

school screening, pre-marital counselling)

• To use framework in standardizing care of other genetic disorders

Policy Framework

“There is no passion to be found playing small - in settling for a life that is less than the one you are capable of living.”

Nelson Mandela la Former President of South Africa

Thank You

This is presentation reflects only the author(s)’s view and the EU Research Executive Agency (R (REA) is is not responsible for any use that may be made of f the in information it it contains.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie gr grant agr agreement No.

• . 82

8240 4021 21